March 7, 2023
Teijin Pharma said on March 6 that it has agreed to grant exclusive worldwide rights to develop, manufacture, and commercialize its preclinical small molecule candidate for proteinuric kidney disease to Swiss giant Novartis. Under their agreement, the Japanese company will...read more